NCT06582485View on ClinicalTrials.gov

A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Ischemia-reperfusion InjuryKidney Transplant; Complications

Interventions

DRUG

iCM012 solution 2 mg/mL

200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.

DRUG

Placebo

200 mL IMP solution is administered ex vivo by gravity as single infusion through the renal artery/-ies over a period of 5-10 minutes.

All Listed Sponsors

lead

iCoat Medical AB

INDUSTRY

NCT06582485 - A Trial to Assess Efficacy and Safety of ex Vivo Allograft Admin of iCM012 Solution 2 mg/ml to Improve Its Function in Recipients of DCD Kidneys | Biotech Hunter | Biotech Hunter